



Contents lists available at ScienceDirect

## Gynecologic Oncology

journal homepage: [www.elsevier.com/locate/ygyno](http://www.elsevier.com/locate/ygyno)

## Corrigendum

Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” [Gynecol. Oncol. 151 (2018) 18–23]



Alexander B. Olawaiye <sup>a,\*</sup>, James J. Java <sup>b</sup>, Thomas C. Krivak <sup>c</sup>, Michael Friedlander <sup>d</sup>, David G. Mutch <sup>e</sup>, Gretchen Glaser <sup>f</sup>, Melissa Geller <sup>g</sup>, David M. O'Malley <sup>h</sup>, Robert M. Wenham <sup>i</sup>, Roger B. Lee <sup>j</sup>, Diane C. Bodurka <sup>k</sup>, Thomas J. Herzog <sup>l</sup>, Michael A. Bookman <sup>m</sup>

<sup>a</sup> Division of Gynecologic Oncology, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States of America

<sup>b</sup> NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States of America

<sup>c</sup> Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Western Pennsylvania Hospital, Pittsburgh, PA, United States of America

<sup>d</sup> Prince of Wales Clinical School UNSW, Department of Medical Oncology, The Prince of Wales Hospital, Sydney, Australia

<sup>e</sup> Dept. of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, MO 63110, United States of America

<sup>f</sup> Gynecologic Oncology, Carilion Clinic Gynecological Oncology, Roanoke, VA 24016, United States of America

<sup>g</sup> Dept. of Obstetrics, Gynecology and Women's Health, University of Minnesota Medical Center-Fairview, Minneapolis, MN 55455, United States of America

<sup>h</sup> Dept. of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United States of America

<sup>i</sup> Department of Gynecologic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States of America

<sup>j</sup> Tacoma General Hospital, Tacoma, WA, United States of America

<sup>k</sup> Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America

<sup>l</sup> Dept. of Obstetrics & Gynecology, University of Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, OH 45267, United States of America

<sup>m</sup> The Permanente Medical Group, Inc., 2350 Geary Blvd, Room 115, San Francisco, CA 94115, United States of America

The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below:

Dr. Wenham reports being a research fund recipient, consultant, advisor, steering committee or DSMB member, or speaker for Tesaro, Clovis, Genentech, Merck, Ovation Diagnostics, Janseen, Mersana, and Tapimmune. The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ygyno.2018.07.021>.

\* Corresponding author.

E-mail address: [olawaiyea@mail.magee.edu](mailto:olawaiyea@mail.magee.edu) (A.B. Olawaiye).

<https://doi.org/10.1016/j.ygyno.2018.10.022>

0090-8258/© 2018 Elsevier Inc. All rights reserved.